Overview

Pharmacokinetic, Safety and Efficacy of Intermittent Application of Caspofungin for Antifungal Prophylaxis

Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
The study is a pilot phase II, prospective, non-comparative, single center trial aimed to evaluate pharmacokinetic and safety of an intermittent dosing schedule for antifungal prophylaxis in high risk patients.
Phase:
Phase 2
Details
Lead Sponsor:
Werner J. Heinz
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Antifungal Agents
Caspofungin
Echinocandins
Miconazole